Large scale experience of two ultrahypofractionated 5 fractions regimes after breast conserving surgery from a single centre

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Cancer Tomorrow. [Internet]. International Agency for Research in cancer, World Health Organisation; 2023. https://gco.iarc.fr/tomorrow/
   Google Scholar
• Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet Lond Engl. 2011;378(9804):1707–1716.
   PubMed Web of Science ®Google Scholar
• McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet Lond Engl. 2014;383(9935):2127–2135.
   PubMed Web of Science ®Google Scholar
• Freedman GM. Radiation therapy for operable breast cancer: sixty years of progress as seen through the articles published in the journal cancer. Cancer. 2008;113(7 Suppl):1779–1800. doi: 10.1002/cncr.23646.
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Agrawal RK, Aird EGA, et al. The UK standardisation of breast radiotherapy (START) trial a of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331–341.
   PubMed Web of Science ®Google Scholar
• The UK Standardisation of Breast Radiotherapy (START). Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098–1107.
   PubMed Web of Science ®Google Scholar
• Kacprowska A, Jassem J. Hypofractionated radiotherapy for early breast cancer: review of phase III studies. Rep Pract Oncol Radiother. 2012;17(2):66–70. doi: 10.1016/j.rpor.2011.10.003.
   PubMedGoogle Scholar
• Offersen BV, Alsner J, Nielsen HM, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial. J Clin Oncol. 2020;38(31):3615–3625. doi: 10.1200/JCO.20.01363.
   PubMed Web of Science ®Google Scholar
• Vicini FA, Winter K, Freedman GM, et al. NRG RTOG 1005: a phase III trial of hypo fractionated whole breast irradiation with concurrent boost vs. conventional whole breast irradiation plus sequential boost following lumpectomy for high risk early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2022;114(3):S1. doi: 10.1016/j.ijrobp.2022.07.2320.
   PubMed Web of Science ®Google Scholar
• UNICANCER. Multicenter randomized phase III trial comparing hypofractionated versus standard radiotherapy in breast cancer with an indication for regional lymph node irradiation in terms of lymphedema occurrence [Internet]. clinicaltrials.gov. 2023. Report No. NCT03127995. https://clinicaltrials.gov/ct2/show/NCT03127995.
   Google Scholar
• Kirova YM, Campana F, Savignoni A, et al. Breast-conserving treatment in the elderly: long-term results of adjuvant hypofractionated and normofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2009;75(1):76–81. doi: 10.1016/j.ijrobp.2008.11.005.
   PubMed Web of Science ®Google Scholar
• Ortholan C, Hannoun-Lévi JM, Ferrero JM, et al. Long-term results of adjuvant hypofractionated radiotherapy for breast cancer in elderly patients. Int J Radiat Oncol Biol Phys. 2005;61(1):154–162. doi: 10.1016/j.ijrobp.2004.04.059.
   PubMed Web of Science ®Google Scholar
• Agrawal RK, Alhasso A, Barrett-Lee PJ, et al. First results of the randomised UK FAST trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol J Eur Soc Ther Radiol Oncol. 2011;100(1):93–100.
   PubMed Web of Science ®Google Scholar
• Brunt AM, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613–1626. doi: 10.1016/S0140-6736(20)30932-6.
   PubMed Web of Science ®Google Scholar
• Chaffai I, Cao K, Kissel M, et al. Patient selection and early tolerance of whole breast irradiation according to the « fast forward » protocol: preliminary results]. Cancer Radiother. 2022;26(4):542–546. doi: 10.1016/j.canrad.2021.07.036.
   PubMed Web of Science ®Google Scholar
• Fournier-Bidoz N, Kirova YM, Campana F, et al. Simplified field-in-field technique for a large-scale implementation in breast radiation treatment. Med Dosim. 2012;37(2):131–137. doi: 10.1016/j.meddos.2011.03.002.
   PubMed Web of Science ®Google Scholar
• Kirova YM, Hijal T, Campana F, et al. Whole breast radiotherapy in the lateral decubitus position: a dosimetric and clinical solution to decrease the doses to the organs at risk (OAR). Radiother Oncol. 2014;110(3):477–481. doi: 10.1016/j.radonc.2013.10.038.
   PubMed Web of Science ®Google Scholar
• Msika R, Fourquet A, Laki F, et al. Institut curie guidelines on breast target volume delineation for patients treated in lateral position. Cancer Radiother. 2020;24(8):795–798. doi: 10.1016/j.canrad.2020.08.044.
   PubMed Web of Science ®Google Scholar
• Dragun AE, Ajkay NJ, Riley EC, et al. First results of a phase 2 trial of once-weekly hypofractionated breast irradiation (WHBI) for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2017;98(3):595–602. doi: 10.1016/j.ijrobp.2017.01.212.
   PubMed Web of Science ®Google Scholar
• Eldredge-Hindy H, Pan J, Rai SN, et al. A phase II trial of once weekly hypofractionated breast irradiation for early stage breast cancer. Ann Surg Oncol. 2021;28(11):5880–5892. doi: 10.1245/s10434-021-09777-3.
   PubMed Web of Science ®Google Scholar
• Sigaudi V, Zannetti M, Ferrara E, et al. Ultra-hypofractionation for whole-breast irradiation in early breast cancer: interim analysis of a prospective study. Biomedicines. 2022;10(10):2568. doi: 10.3390/biomedicines10102568.
   PubMed Web of Science ®Google Scholar
• Nugent K, Quinlan E, Cleary S, et al. Implementation of 26 Gy in five fractions over 1 week adjuvant radiotherapy for breast cancer: prospective report of acute skin toxicity and consideration of resource implications. Breast. 2023;67:55–61. doi: 10.1016/j.breast.2022.12.008.
   PubMed Web of Science ®Google Scholar
• Piras A, Menna S, D'Aviero A, et al. New fractionations in breast cancer: a dosimetric study of 3D-CRT versus VMAT. J Med Radiat Sci. 2022;69(2):227–235. doi: 10.1002/jmrs.530.
   PubMed Web of Science ®Google Scholar
• Vrieling C, van Werkhoven E, Maingon P, et al. Prognostic factors for local control in breast cancer after long-term follow-up in the EORTC boost vs no boost trial: a randomized clinical trial. JAMA Oncol. 2017;3(1):42–48. doi: 10.1001/jamaoncol.2016.3031.
   PubMed Web of Science ®Google Scholar
• Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25(22):3259–3265. doi: 10.1200/JCO.2007.11.4991.
   PubMed Web of Science ®Google Scholar
• Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16(1):47–56. doi: 10.1016/S1470-2045(14)71156-8.
   PubMed Web of Science ®Google Scholar
• Montero A, Ciérvide R, Cañadillas C, et al. Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer. Clin Transl Radiat Oncol. 2023;41:100651. https://www.ctro.science/article/S2405-6308(23)00076-9/fulltext
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Chatterjee S. HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results – Interim analysis. Radiother Oncol. 2022;174:59–68. doi: 10.1016/j.radonc.2022.07.003.
   PubMed Web of Science ®Google Scholar
• Kunkler IH, Williams LJ, Jack WJL, et al. Breast-conserving surgery with or without irradiation in early breast cancer. N Engl J Med. 2023;388(7):585–594. doi: 10.1056/NEJMoa2207586.
   PubMed Web of Science ®Google Scholar